Genetic Technologies Limited (NASDAQ:GENE) shares, rose in value on Wednesday, 06/09/21, with the stock price down by -9.52% to the previous day’s close as strong demand from buyers drove the stock to $3.99.
Actively observing the price movement in the recent trading, the stock is buoying the session at $4.41, falling within a range of $3.80 and $5.18. Referring to stock’s 52-week performance, its high was $10.30, and the low was $1.97. On the whole, GENE has fluctuated by 12.79% over the past month.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that GENE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a Hold.
1 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 1 recommend it as a Buy and 0 called the GENE stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of GENE currently trading nearly 3.99% and 0.10% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.61, while the 7-day volatility ratio is showing 10.55% which for the 30-day chart, stands at 7.28%. Furthermore, Genetic Technologies Limited (GENE)’s beta value is 2.51, and its average true range (ATR) is 0.31. The company’s stock has been forecasted to trade at an average price of $25.65 over the course of the next 52 weeks, with a low of $25.65 and a high of $25.65. Based on these price targets, the low is -542.86% off current price, whereas the price has to move -542.86% to reach the yearly target high. Additionally, analysts’ median price of $25.65 is likely to be welcomed by investors because it represents a decrease of -542.86% from the current levels.
A comparison of Genetic Technologies Limited (GENE) with its peers suggests the former has fared considerably weaker in the market. GENE showed an intraday change of -9.52% in today’s session so far, and over the past year, it grew by 113.56%%. In comparison, Quest Diagnostics Incorporated (DGX) has moved higher at 0.48% today and is up 9.22% over the past 12 months. On the other hand, the price of Thermo Fisher Scientific Inc. (TMO) has risen 2.61% today. The stock, however, is off 28.93% from where it was a year ago. Additionally, there is a gain of 0.80% for Laboratory Corporation of America Holdings (LH) in recent trading while the stock has seen an overall depriciation of 44.85%% over the past year. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it gained 0.39%. Meanwhile, the Dow Jones Industrial Improved by 0.34%.
Data on historical trading for Genetic Technologies Limited (NASDAQ:GENE) indicates that the trading volumes over the past 10 days have averaged 1.64 million and over the past 3 months, they’ve averaged 967.57K. According to company’s latest data on outstanding shares, there are 13.64 million shares outstanding.
Nearly 86.50% of Genetic Technologies Limited’s shares belong to company insiders and institutional investors own 2.70% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.05 million shares as on May 27, 2021, resulting in a short ratio of 2.47. According to the data, the short interest in Genetic Technologies Limited (GENE) stood at 6.99% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 1.22 million. The stock has risen by 22.50% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the GENE stock heading into the next quarter.